Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma

Abstract

Recent studies have shown that circulating microRNAs are a potential biomarker in various types of malignancies. The aim of this study was to investigate the feasibility of using serum exosomal microRNAs as novel serological biomarkers for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We measured the serum exosomal microRNAs and serum circulating microRNAs in patients with CHB (n=20), liver cirrhosis (LC) (n=20) and HCC (n=20). Serum exosomal microRNA was extracted from 500 μl of serum using an Exosome RNA Isolation kit. The expression levels of microRNAs were quantified by real-time PCR. The expression levels of selected microRNAs were normalized to Caenorhabditis elegans microRNA (Cel-miR-39). The serum levels of exosomal miR-18a, miR-221, miR-222 and miR-224 were significantly higher in patients with HCC than those with CHB or LC (P<0.05). Further, the serum levels of exosomal miR-101, miR-106b, miR-122 and miR-195 were lower in patients with HCC than in patients with CHB (P=0.014, P<0.001, P<0.001 and P<0.001, respectively). There was no significant difference in the levels of miR-21 and miR-93 among the three groups. Additionally, the serum levels of circulating microRNAs showed a smaller difference between HCC and either CHB or LC. This study suggests that serum exosomal microRNAs may be used as novel serological biomarkers for HCC. Liver cancer could be detected by measuring blood levels of microRNA molecules, according to Korean researchers. A team led by Yong-Han Paik at the Sungkyunkwan University School of Medicine, South Korea, made the discovery by measuring blood levels of ten microRNA molecules found in exosomes. These cell-derived membrane-bound packages circulate in the blood, their contents including protein and RNA. MicroRNA levels were measured in the blood of patients with hepatocellular carcinoma, a form of liver cancer, and compared to those in patients with liver cirrhosis or chronic hepatitis B. In patients with liver cancer, some microRNA molecules were present at higher levels and some at lower levels than in other patients. The findings suggest that microRNA levels could form the basis of a simple blood test to diagnose liver cancer.